Ionis Pharmaceuticals, Inc.

Equities

IONS

US4622221004

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:59 2024-03-28 pm EDT 5-day change 1st Jan Change
43.34 USD -2.96% Intraday chart for Ionis Pharmaceuticals, Inc. +1.36% -14.35%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Ionis Pharmaceuticals, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-20-2024 10:30 AM
Sector Update: Health Care Stocks Gain Premarket Wednesday MT
Ionis Pharmaceuticals' Phase 2 Study of ION224 Achieves Liver Histologic Improvement; Shares Up MT
Ionis Pharma's fatty liver disease drug succeeds in mid-stage trial RE
Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224 CI
Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $72 From $65, Maintains Outperform Rating MT
Transcript : Ionis Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 11:10 AM
Ionis Pharmaceuticals, Inc. Announces Executive Changes CI
Oppenheimer Adjusts Ionis Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating MT
Travere drug for rare kidney condition recommended for EU approval RE
Transcript : Ionis Pharmaceuticals, Inc., 2023 Earnings Call, Feb 21, 2024
Sector Update: Health Care Stocks Flat to Lower Premarket Wednesday MT
Ionis Pharmaceuticals' Q4 Net Loss Narrows as Revenue Increases; Provides 2024 Revenue Guidance; Shares Gain Pre-Bell MT
Earnings Flash (IONS) IONIS PHARMACEUTICALS Posts Q4 Revenue $325M MT
Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024 CI
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ionis Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS CI
GSK: fast track approval for hepatitis treatment in the USA CF
Ionis Pharmaceuticals Says US FDA Grants Fast Track Designation to Eplontersen MT
Ionis Pharmaceuticals Insider Sold Shares Worth $1,160,303, According to a Recent SEC Filing MT
JPMorgan Chase Adjusts Price Target on Ionis Pharmaceuticals to $55 From $52, Maintains Neutral Rating MT
Ionis Pharmaceuticals Insider Sold Shares Worth $333,788, According to a Recent SEC Filing MT
RBC Lifts Price Target on Ionis Pharmaceuticals to $70 From $65, Says Survey Suggests Wainua Launch May Surprise to Upside; Outperform Kept MT
Chart Ionis Pharmaceuticals, Inc.
More charts
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
44.66 USD
Average target price
56.72 USD
Spread / Average Target
+27.00%
Consensus
  1. Stock
  2. Equities
  3. Stock Ionis Pharmaceuticals, Inc. - Nasdaq
  4. News Ionis Pharmaceuticals, Inc.
  5. Ionis Pharmaceuticals' Cardiovascular Risk Reduction Therapy in Phase 2b Development at Pfizer Meets Primary Endpoint